Aristotelis Nastos

Fasciotens GmbH engages in the development of external medical device that provides solution for the open abdomen or abdominal compartment syndrome. It offers fasciotens abdomen. The company was founded by Gereon Lill and Frank Beyer in 2016 and is headquartered in Essen, Germany.

Cryotherapeutics SA develops and markets a cryotherapy system, with focus on highlighting the safety and efficacy of cryoneergy in the cardiovascular system. The firm specializes in the design of a proprietary system to be used in the treatment of coronary artery diseases that cause heart attacks. Its focus areas encompass technology research, system development, and early-stage product commercialization. The company was founded by Randell L. Werneth, John Yianni and Maurice Buchbinder on September 8, 2009 and is headquartered in Cologne, Germany.

Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany.

Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany.

Resolve BioSciences GmbH is a German company that applies molecular cartography to provide scientists with a high-resolution view of spatial biology. The company is based in Monheim am Rhein, Germany. The company's proprietary technology offers full spatial context at subcellular resolution, which helps scientists detect individual transcripts and rare signals to interpret fundamental biology. The company's technology is used in critical fields such as oncology, neuroscience, infectious disease, and agriculture. The company was founded by Jason T. Gammack, and John Stark has been the CEO of the company since 2023.

Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany.

Fasciotens GmbH engages in the development of external medical device that provides solution for the open abdomen or abdominal compartment syndrome. It offers fasciotens abdomen. The company was founded by Gereon Lill and Frank Beyer in 2016 and is headquartered in Essen, Germany.

Abalos Therapeutics GmbH engages in the development of an anti-cancer arenavirus-based drug. It focuses on awakening immune responses against tumors and metastases. The company was founded by Karl Lang and Philipp Lang and is headquartered in Essen, Germany.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany.

Cryotherapeutics SA develops and markets a cryotherapy system, with focus on highlighting the safety and efficacy of cryoneergy in the cardiovascular system. The firm specializes in the design of a proprietary system to be used in the treatment of coronary artery diseases that cause heart attacks. Its focus areas encompass technology research, system development, and early-stage product commercialization. The company was founded by Randell L. Werneth, John Yianni and Maurice Buchbinder on September 8, 2009 and is headquartered in Cologne, Germany.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

Cryotherapeutics SA develops and markets a cryotherapy system, with focus on highlighting the safety and efficacy of cryoneergy in the cardiovascular system. The firm specializes in the design of a proprietary system to be used in the treatment of coronary artery diseases that cause heart attacks. Its focus areas encompass technology research, system development, and early-stage product commercialization. The company was founded by Randell L. Werneth, John Yianni and Maurice Buchbinder on September 8, 2009 and is headquartered in Cologne, Germany.

Resolve BioSciences GmbH is a German company that applies molecular cartography to provide scientists with a high-resolution view of spatial biology. The company is based in Monheim am Rhein, Germany. The company's proprietary technology offers full spatial context at subcellular resolution, which helps scientists detect individual transcripts and rare signals to interpret fundamental biology. The company's technology is used in critical fields such as oncology, neuroscience, infectious disease, and agriculture. The company was founded by Jason T. Gammack, and John Stark has been the CEO of the company since 2023.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany.

Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

Abalos Therapeutics GmbH engages in the development of an anti-cancer arenavirus-based drug. It focuses on awakening immune responses against tumors and metastases. The company was founded by Karl Lang and Philipp Lang and is headquartered in Essen, Germany.

Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany.

Resolve BioSciences GmbH is a German company that applies molecular cartography to provide scientists with a high-resolution view of spatial biology. The company is based in Monheim am Rhein, Germany. The company's proprietary technology offers full spatial context at subcellular resolution, which helps scientists detect individual transcripts and rare signals to interpret fundamental biology. The company's technology is used in critical fields such as oncology, neuroscience, infectious disease, and agriculture. The company was founded by Jason T. Gammack, and John Stark has been the CEO of the company since 2023.

Cryotherapeutics SA develops and markets a cryotherapy system, with focus on highlighting the safety and efficacy of cryoneergy in the cardiovascular system. The firm specializes in the design of a proprietary system to be used in the treatment of coronary artery diseases that cause heart attacks. Its focus areas encompass technology research, system development, and early-stage product commercialization. The company was founded by Randell L. Werneth, John Yianni and Maurice Buchbinder on September 8, 2009 and is headquartered in Cologne, Germany.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany.

Abalos Therapeutics GmbH engages in the development of an anti-cancer arenavirus-based drug. It focuses on awakening immune responses against tumors and metastases. The company was founded by Karl Lang and Philipp Lang and is headquartered in Essen, Germany.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

Abalos Therapeutics GmbH engages in the development of an anti-cancer arenavirus-based drug. It focuses on awakening immune responses against tumors and metastases. The company was founded by Karl Lang and Philipp Lang and is headquartered in Essen, Germany.

DIREVO Industrial Biotechnology GmbH provides bioengineering services for industrial, molecular biology, and reaction chemistry applications. It offers enzyme and strain engineering, application development, and process engineering services. The firm also offers research and development services for bio-fuel production. The company was founded in July 2008 and is headquartered in Cologne, Germany.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany.

DIREVO Industrial Biotechnology GmbH provides bioengineering services for industrial, molecular biology, and reaction chemistry applications. It offers enzyme and strain engineering, application development, and process engineering services. The firm also offers research and development services for bio-fuel production. The company was founded in July 2008 and is headquartered in Cologne, Germany.

NRW.Bank (Private Equity) (NRWB PE) is the private equity operating division of the NRW Bank which traces their origins to 2002 when Westdeutsche Landesbank Girozentrale was split up into two entities. From this basis and further to the 2004 Reorganization Act, the current foundations for NRW Bank were established. Headquartered in Dusseldorf, Germany, NRWB PE specializes in providing capital and business development support for SMEs in North Rhine-Westphalia. They manage a number of private equity funds. Through mezzanine capital as a co-investor alongside lead investors, they provide equity limited to minority stakes as a silent partner.

CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany.